Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn., July 08, 2025--(BUSINESS ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company currently trading near $0.34 per share, has agreed to sell its interest in REV102, a preclinical ENPP1 ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...
(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...
कुछ परिणाम छुपे हुए हैं क्योंकि हो सकता है वे आपके लिए पहुँच योग्य न हों.
पहुँच से बाहर के परिणामों को दिखाएँ
प्रतिक्रिया